ライフサイエンスコーパス: life expectancy

1 h the risk of suicide, result in a shortened life expectancy.

2 fe loss without treatment from the 11.0-year life expectancy.

3 cular disorders, which contribute to reduced life expectancy.

4 K have been associated with a step-change in life expectancy.

5 rson-years) and a 6-year reduction in median life expectancy.

6 tanding of the income-related differences in life expectancy.

7 r 310 person-years and a 6-year reduction in life expectancy.

8 imate annual public direct medical costs and life expectancy.

9 eople living with HIV now have a much longer life expectancy.

10 often lead to profound differences in adult life expectancy.

11 patients' stroke risk, hemorrhage risk, and life expectancy.

12 who have both high lung cancer risk and long life expectancy.

13 sonalized treatment selection likely extends life expectancy.

14 the central part of the city had the highest life expectancy.

15 relative risks or crude estimates of reduced life expectancy.

16 might be contributing to the disparities in life expectancy.

17 ular disease death, all-cause mortality, and life expectancy.

18 creasing educational differences in US adult life expectancy.

19 e survival were used to estimate the loss in life expectancy.

20 cular and all-cause mortality, and increased life expectancy.

21 ity risk and medical costs and reductions in life expectancy.

22 association between daily PM2.5 exposure and life expectancy.

23 patients with CML to experience near-normal life expectancy.

24 : Smoking results in at least a decade lower life expectancy.

25 ave witnessed an unprecedented rise in human life expectancy.

26 ts, with the aim of enhancing healthspan and life expectancy.

27 , symptoms, and worsening quality of life or life expectancy.

28 eighed against other patient factors such as life expectancy.

29 d dietary habits in relation to disease-free life expectancy.

30 ency, reduced quality of life, and a shorter life expectancy.

31 ated mortality, and to adjust for changes in life-expectancy.

32 luent areas of the United States have longer life expectancies.

33 p (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1

34 aparoscopy experienced longer 3-year average life expectancy (+6.2%, P = 0.018), and those who live p

35 Men with the lowest 1% income had the lowest life expectancy (70.6 years [95% CI, 69.6-71.6]), which

36 Survival models were applied to predict life expectancy, adjusting for ethnicity, working status

37 Contemporary data on loss in life expectancy after aortic valve replacement (AVR) are

38 term relative survival and estimated loss in life expectancy after AVR.

39 With increased life expectancy, age-associated cognitive decline become

40 timates of life expectancy at birth, healthy life expectancy, all-cause and cause-specific mortality,

41 ds regression model to compare mortality and life expectancy among patients treated with either baria

42 Improvements in life expectancy among people living with human immunodef

43 eaths among PLWH could narrow disparities in life expectancy among some key populations, but other ca

44 ducts grew manifold, allowing an increase in life expectancy and a better life quality for humans and

45 tend not to differentiate between extending life expectancy and adding healthy years.

46 alized people with HIV is likely to increase life expectancy and be cost-effective at the currently a

47 ospitalised patients with HIV could increase life expectancy and be cost-effective in resource-limite

48 y improvements and long-run quality-adjusted life expectancy and costs.

49 aminin-111 protein results in an increase in life expectancy and improvements in muscle pathology and

50 the central part of the city had the lowest life expectancy and in Belo Horizonte the central part o

51 Our results demonstrate that both changes in life expectancy and life span equality are weighted tota

52 In recent decades, life expectancy and life span equality have occasionally

53 The link between life expectancy and life span equality is especially str

54 re, we develop a unifying framework to study life expectancy and life span equality over time, relyin

55 We study the dynamic relationship between life expectancy and life span equality with reliable dat

56 Some recent exceptions to the joint rise of life expectancy and life span equality, however, make it

57 ife expectancy is the key to increasing both life expectancy and life span equality.

58 es at which reductions in mortality increase life expectancy and life span equality: the more progres

59 ed into a microsimulation model to calculate life expectancy and lifetime event risk for the ages of

60 Life expectancy and long-term costs associated with devi

61 pair suggest that younger patients with long life expectancy and low-perioperative risk may benefit m

62 m by providing both greater quality-adjusted life expectancy and lower long-term costs than SAVR.

63 diagnosis that is likely related to limited life expectancy and physical limitations in ALS patients

64 condary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy com

65 ffective contribution to the prolongation of life expectancy and quality.

66 and Death) clock, which accurately predicts life expectancy and the efficacy of a lifespan-extending

67 especially in light of the increases in the life expectancy and the incidence of comorbidities in th

68 is in Zimbabwe will improve survival, extend life expectancy, and be cost-effective for HIV-exposed i

69 ental health, cognitive performance, overall life expectancy, and increases vulnerability to Alzheime

70 g model inputs: infection-related mortality, life expectancy, and infection cost.

71 Model outcomes included survival, life expectancy, and mean lifetime per-person treatment

72 C tumor burden, degree of liver dysfunction, life expectancy, and patient preferences.

73 risk of mortality, direct medical costs, and life expectancy are unknown.

74 Life expectancy at 40 years of age and cause-specific mo

75 HIV-free life expectancy at age 15 years improved significantly d

76 We sought to estimate life expectancy at age 20 years in key populations (and

77 Between 2010 and 2017, life expectancy at age 25 significantly declined among w

78 In contrast, life expectancy at age 25 significantly increased among

79 CVD stagnation held back the increase of US life expectancy at age 25 y by 1.14 y in women and men,

80 Life expectancy at age 25 years and years of life lost b

81 this serial cross-sectional study, estimated life expectancy at age 25 years declined overall between

82 about 70%, 160%, and 280%, respectively; and life expectancy at age 60 years decreased by about 5, 10

83 Of total life expectancy at age 65, 5.7% (1.0 year (95% CI: 1.0,

84 erence between the ninth and first decile of life expectancy at birth (P90-P10 gap) across subcity un

85 alth have focused on broad measures, such as life expectancy at birth and child and infant mortality,

86 are evident in the effects of low supply on life expectancy at birth and high mortality across ages,

87 We also analysed the association between life expectancy at birth and socioeconomic status at the

88 We calculated average life expectancy at birth by sex and subcity unit with li

89 We saw an increase in life expectancy at birth from east to west in Panama Cit

90 e found large spatial differences in average life expectancy at birth in Latin American cities, with

91 Life expectancy at birth increased by 5.4 (95% UI 3.7-7.

92 the numbers of deaths and in life years and life expectancy at birth, attributable to changes in PM2

93 We used GBD 2016 estimates of life expectancy at birth, healthy life expectancy, all-c

94 e for 2016, and actuarial data for remaining life expectancy at the age of death.

95 ol-related mortality would have the greatest life-expectancy benefit for black men who have sex with

96 et quality with cardiometabolic disease-free life expectancy between ages 50 and 85 y.

97 associated with cardiometabolic disease-free life expectancy between ages 50 and 85.

98 There was no difference in loss in life expectancy between men and women.

99 The largest differences in life expectancy between Norway and United States were fo

100 Differences in life expectancy between the top and bottom 5% of the cPR

101 HA will strive to equitably increase healthy life expectancy beyond current projections, with global

102 tic neuroendocrine carcinoma who has a short life expectancy but feels well and has no symptoms relat

103 Current treatments increase life expectancy but have limited impact on the progressi

104 HIV testing alone increased life expectancy by 0.07-0.30 years in MSM; PrEP added ap

105 se with CVD) was projected to increase their life expectancy by 0.19 (0.14-0.23) and 0.90 (0.50-1.21)

106 with Xpert+AlereLAM, Xpert+FujiLAM increased life expectancy by 0.2 years for those tested in South A

107 The intervention increased life expectancy by 0.5-1.2 years and was cost-effective,

108 time horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-

109 a 35% 5-year PFS, tisagenlecleucel increased life expectancy by 4.6 years at $168,000/QALY gained (95

110 ssion-free survival (PFS), axi-cel increased life expectancy by 8.2 years at $129,000/QALY gained (95

111 We also examined life expectancy by age at diagnosis.

112 These deaths would lower national life expectancy by an estimated 0.15 years (0.13-0.17) f

113 We aimed to assess the potential benefits in life expectancy by attaining the daily PM2.5 standards i

114 From 2005 to 2015, the differences in life expectancy by income increased, largely attributabl

115 here were substantial and increasing gaps in life expectancy by income level from 2005 to 2015.

116 Differences in life expectancy by income levels in Norway were similar

117 Along with extended life expectancy comes a growing population that is exper

118 diabetes had higher risk of death and lower life expectancy compared to the general population.

119 creases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cos

120 , elite endurance athletes have an increased life expectancy compared with the general population.

121 nsmissions from ages 15-30, quality-adjusted life expectancy, costs, and incremental cost-effectivene

122 is study indicates that significantly longer life expectancy could be achieved by a reduction in the

123 Given the economic wealth of Russia, its life expectancy could be substantially higher.

124 The recent decrease in US life expectancy culminated a period of increasing cause-

125 Life expectancy data for 1959-2016 and cause-specific mo

126 ing gun violence epidemic and reverse recent life expectancy declines among Americans.

127 ut the rate of increase slowed over time and life expectancy decreased after 2014.

128 lar level of income, the largest part of the life expectancy deficit was produced by working-age mort

129 gton D.C.; second, we decomposed black-white life expectancy differences into 23 causes of death in t

130 cases to live male births by year of birth, life expectancy disadvantage as a 1 - ratio of prevalenc

131 The life expectancy disadvantage for high-income countries i

132 Patients with hemophilia still have a life expectancy disadvantage.

133 We calculate the impact on period life expectancy (down 2.94 y) and remaining life years (

134 ally selects older ever-smokers with shorter life expectancies due to comorbidities.

135 nal function, routine PN yielded the longest life expectancy (eg, 0.67 years in 65-year-old men with

136 RI guidance for active surveillance extended life expectancy (eg, 2.60 years for MRI vs PN in CKD 3a,

137 y or active surveillance for growth extended life expectancy (eg, 2.70 years for surveillance for gro

138 ioeconomic status was associated with higher life expectancy, especially in Santiago (change in life

139 sis is debilitating and associated with poor life expectancy, especially in those with cardiac dysfun

140 the economic value of an additional year of life expectancy; estimated total implementation costs; a

141 racted cause-specific mortality and HIV-free life expectancy estimates from the Global Burden of Dise

142 ic mastocytosis (ISM) patients have a normal life expectancy, except in the 5% to 10% of cases that p

143 iet quality and cardiometabolic disease-free life expectancy followed a dose-response pattern and was

144 nd 0.06 (95% CI: 0.04-0.07) years of gain in life expectancy for each death in these cities.

145 The marked increase in life expectancy for HIV-1 seropositive individuals, foll

146 Furthermore, the overall life expectancy for participants without these risk fact

147 n is the only intervention shown to increase life expectancy for patients with IPF, but it is associa

148 However, although life expectancy for people with cystic fibrosis has incr

149 e risk of any NCD, age at onset, and overall life expectancy for strata of 3 shared risk factors at b

150 Critically, weight gain may reduce life expectancy for up to 20-30 years in patients with p

151 Over the same period, life expectancy for women in the highest income quartile

152 increased 3.2 years (95% CI, 2.7-3.7), while life expectancy for women in the lowest income quartile

153 We used per-capita GDP (PPP) and life expectancy from 61 countries in 2014-15, plus those

154 tios with discounted (3% per year) costs and life expectancy from a health-care system perspective fo

155 96 to 477-515 cells/uL) and quality-adjusted life expectancy from age 15 (44.4 to 48.3-48.7 years) am

156 nd sex-specific cardiometabolic disease-free life expectancy from age 50 to 85 y for each AHEI-2010 q

157 ned-based selection would increase the total life expectancy from CT screening (633 400 vs. 607 800 y

158 The net increase in life expectancy from offering early transplantation was

159 the aid of CVD mortality declines, future US life expectancy gains must come from other causes-a monu

160 diminished by about 25% since 2005, when the life expectancy gap was 8.9 years for Russia and 6.6 yea

161 ith spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous ra

162 insufficient for achieving pre-2010 pace of life expectancy growth.

163 Although the black-white gap in life expectancy has been shrinking in the U.S., national

164 ctancy in 2020 will remain higher than Black life expectancy has ever been unless nearly 700,000 exce

165 st common chromosomal condition, and average life expectancy has increased substantially, from 25 yea

166 However, as human life expectancy has increased, so has the number of immu

167 US life expectancy has not kept pace with that of other wea

168 Patient life expectancy has recently increased, but the need for

169 n is a major public health threat to healthy life expectancy; however, little is known of long-term m

170 Life expectancy improved from 48 to 69 years, infant mor

171 Life expectancy in 2015 for both Russia and Moscow lay b

172 Moreover, White life expectancy in 2020 will remain higher than Black li

173 rmine the impact of TAVR valve durability on life expectancy in a cohort of low-risk patients similar

174 ere strongly associated with shorter healthy life expectancy in both countries, attesting to the robu

175 Until 2011-16, male life expectancy in England and Wales followed the median

176 Large spatial differences in life expectancy in Latin American cities and their assoc

177 ts might significantly contribute to reduced life expectancy in low-income and middle-income countrie

178 This study found a shorter life expectancy in patients after AVR compared with the

179 that of surgical valves to result in reduced life expectancy in patients with demographics similar to

180 is the leading contributor to the shortened life expectancy in patients with severe mental illness (

181 e associations between healthy lifestyle and life expectancy in people with and without multimorbidit

182 increasing educational differences in adult life expectancy in recent years.

183 Our objective was to examine inequalities in life expectancy in six large Latin American cities and i

184 The adjusted median life expectancy in the surgery group was 3.0 years (95%

185 Since 2010, the rate of improvement in life expectancy in the UK has slowed.

186 living with HIV/AIDS (PLWHA) have a growing life expectancy in the US due to early provision of effe

187 ignificant factors underlying the decline in life expectancy in the US.

188 applicability of TAVR in patients with long life expectancy in whom THV durability may be a concern.

189 rmine the impact of TAVR valve durability on life expectancy in younger age groups (40, 50, and 60 ye

190 For men, life expectancy increased 3.1 years (95% CI, 2.5-3.7) in

191 US life expectancy increased for most of the past 60 years,

192 Between 1959 and 2016, US life expectancy increased from 69.9 years to 78.9 years

193 Among 92,289 PLWH, life expectancy increased in all key populations and com

194 The estimated loss in life expectancy increased with younger age: 0.4 years (9

195 years), which becomes more favorable as the life expectancy increases beyond 6 years.

196 Increasing life expectancy is causing the prevalence of age-related

197 In Indonesia, the average life expectancy is less than 5 months, with most patient

198 life span equality is especially strong when life expectancy is less than 70 y.

199 Longer life expectancy is one factor thought to contribute to t

200 sustaining a major burn injury on long-term life expectancy is poorly understood.

201 to align medications with goals of care when life expectancy is reduced.

202 Saving lives at ages below life expectancy is the key to increasing both life expec

203 rm relative risk of death, but its effect on life expectancy is unclear.

204 rgan transplant recipients (SOTR), and their life expectancy, is increasing, with higher risk for lon

205 awareness (PA)-the understanding of limited life expectancy-is critical for effective goals of care

206 and comorbidities may aim for a near-normal life expectancy, just as the more select patients enroll

207 ortality, to directly estimate mortality and life expectancy loss due to current PM2.5 pollution and

208 The life expectancy loss due to PM2.5 was largest around Los

209 At any PM2.5 concentration, life expectancy loss was, on average, larger in counties

210 llege degree experienced similar declines in life expectancy (men: -0.89 years [95% CI, -1.07 to -0.7

211 We estimated life expectancies of patients receiving early vs delayed

212 erine, and intestinal rupture and an average life expectancy of <50 years.

213 -0.89; p=0.0015), and an average increase in life expectancy of 1.44 years (95% CI 0.20-2.68; p=0.023

214 of 6.55 life years, compared with an average life expectancy of 1.46 life years for patients offered

215 en aged 75 years or older or in women with a life expectancy of 10 years or less, clinicians should d

216 ults older than 75 years or in adults with a life expectancy of 10 years or less.

217 iteria In Solid Tumors (irRECIST), and had a life expectancy of 12 weeks or longer.

218 Group performance score of 1 or less, and a life expectancy of 12 weeks or more.

219 nslated to a microsimulation-based estimated life expectancy of 21 years (general population: 32 year

220 plantation were estimated to have an average life expectancy of 6.55 life years, compared with an ave

221 capital, reaching $43 000 in 2015 and with a life expectancy of 75.5 years.

222 Gun violence has shortened the average life expectancy of Americans, and better knowledge about

223 o lifespan (lifespan setpoint) determine the life expectancy of any given organism.

224 Oncology Group performance status of 0 or 1, life expectancy of at least 3 months, adequate organ fun

225 Oncology Group performance status of 0-2, a life expectancy of at least 3 months, and at least one m

226 ed and platinum-based chemotherapy and had a life expectancy of at least 3 months.

227 operative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.

228 Oncology Group performance status of 0 or 1, life expectancy of at least 6 months, and adequate haema

229 o have a WHO performance status of 0-2 and a life expectancy of at least 6 months.

230 umor insensitivity to chemotherapy, shortens life expectancy of cancer patients.

231 iretroviral therapy (cART) has increased the life expectancy of HIV patients.

232 The increasing life expectancy of individuals with Cystic Fibrosis (CF)

233 tudy compared mortality rates and decline in life expectancy of Iranian patients with type 2 diabetes

234 HbA1c-targeted treatment for patients with a life expectancy of less than 10 years.

235 osimulation model was constructed to compare life expectancy of management strategies for small renal

236 ve Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnos

237 nths; had an ECOG performance status of 0-1; life expectancy of more than 12 weeks; and adequate bone

238 ence of child loss is accompanied by reduced life expectancy of parents in contemporary affluent popu

239 Increased life expectancy of patients diagnosed with HIV in the cu

240 Although the life expectancy of patients with follicular lymphoma (FL

241 ances in standards of care have extended the life expectancy of patients with kidney failure.

242 of non-invasive metrics that can predict the life expectancy of pre-clinical models.

243 ncy in England and Wales followed the median life expectancy of the comparator group.

244 Overall life expectancy of women ranged from 18.0 years (95% con

245 gressive human malignancies, with an average life expectancy of ~6 months from the time of diagnosis.

246 fe and are associated with an alarmingly low life expectancy (on average only 2 years from the amputa

247 schooling years) on a variety of disease and life-expectancy outcomes.

248 The poor performance of female life expectancy over the long-term is in part driven by

249 Reductions in firearm deaths would improve life expectancy, particularly for black men in the USA,

250 proach, predicted quality of life, predicted life expectancy, patient preferences, and other patient

251 having high comorbidity rates and shortened life expectancy, patients with ESKD may harbor unrealist

252 xpectancy, especially in Santiago (change in life expectancy per P90-P10 change unit-level of educati

253 We further estimated the potential gains in life expectancy (PGLE) by assuming that ambient PM2.5 ha

254 cted to be inversely linked to the remaining life expectancy, potentially resulting in a terminal eff

255 eatment after muscle disease onset increased life expectancy, promoted muscle growth and increased mu

256 We aimed to estimate quality-adjusted life expectancy (QALE) loss due to dental conditions in

257 a common practice due to its great impact on life expectancy, quality of life and healthcare costs.

258 For men, life expectancy ranged from 15.6 years (95% CI: 15.4, 15

259 With freshwater mussel life expectancy ranging from a few years up to 200 years

260 S$24 800 and witnessing a 6-year increase in life expectancy, reaching 71.4 years by 2015.

261 GNIFICANCE STATEMENT As a result of enhanced life expectancy, researchers have devoted increasing att

262 y transplant to selected patients who have a life expectancy shorter than the time it would take for

263 ith disability-free and chronic disease-free life expectancy similarly in two longitudinal studies of

264 We compared sex-specific trends in life expectancy since 1970 and age-specific mortality in

265 many countries have seen slower increases in life expectancy since 2011, trends in England and Wales

266 In 2011-16, the rate of improvement in life expectancy slowed sharply for both sexes in England

267 ter decades of robust growth, the rise in US life expectancy stalled after 2010.

268 ve effort negatively covaries with remaining life expectancy, supporting optimality theory and confir

269 han 36 of the comparator countries but lower life expectancy than 60 comparator countries.

270 bariatric surgery was associated with longer life expectancy than usual obesity care.

271 Although PLHIV are experiencing longer life expectancies, this achievement may be undermined by

272 IV diagnosis improved projected undiscounted life expectancy to 25.5 years among infants with HIV and

273 With increasing life expectancy, TTNtv-associated morbidity and mortalit

274 We adjusted life expectancy values for Moscow for underestimation of

275 etween the observed and the Preston-expected life expectancy values for Russia have diminished by abo

276 adult life and do not quit lose a decade of life expectancy versus non-smokers.

277 Otherwise, personalized strategies extended life expectancy versus routine PN: in CKD stages 2 or 3a

278 ase scenario, the standardized difference in life expectancy was <0.10 between TAVR and SAVR until tr

279 The loss in life expectancy was 1.9 years (95% CI: 1.2 to 2.6 years)

280 rly infant diagnosis, projected undiscounted life expectancy was 22.7 years for infants with HIV and

281 es of daily living and, chronic disease-free life expectancy was based on chronic health conditions.

282 By contrast, female life expectancy was below the median and is among the lo

283 Disability-free life expectancy was estimated using repeat measures of l

284 s observed in the United States, except that life expectancy was higher in Norway in the lower to mid

285 Life expectancy was highest for women with income in the

286 Although early survival was good, long-term life expectancy was low.

287 The net increase in life expectancy was maintained in all simulated extreme

288 In younger patients, life expectancy was reduced when TAVR durability was 30%

289 The estimated loss in life expectancy was substantial, and increased with youn

290 Whilst early survival was good, long-term life-expectancy was low.

291 erformance status 0-3, and at least 3 months life expectancy were eligible.

292 At a 30% 5-year PFS, improvements in life expectancy were more modest (6.4 years) and expensi

293 Endurance capacity and life expectancy were normal.

294 At a 25% 5-year PFS, improvements in life expectancy were smaller (3.4 years) and more expens

295 2015) and the potential increase in expected life expectancy with a simulated 20% reduction in drug-

296 Reliable population estimates of life expectancy with dementia are required for shaping h

297 ental disorders were associated with shorter life expectancies, with excess LYLs ranging from 5.42 ye

298 ssociated with mortality impacts and loss of life expectancy, with larger impacts in counties with lo

299 festyle risk factors equally correlated with life expectancy, with smoking being significantly worse

300 R) use is increasing in patients with longer life expectancy, yet robust data on the durability of tr